DIRAS3 and non-small cell lung carcinoma: Altogether, the aforementioned findings and evidence indicate that DIRAS3 inhibits the activation of the RAS/ERK pathway in NSCLC cells, thereby inhibiting NSCLC cell migration and invasion.